Human Islet Research Network
Menu

NIH Announcements

  • HIRN Funding Announcement

    • RFA-DK-18-014: Consortium on Targeting and Regeneration (CTAR)
      This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).

      NIDDK intends to commit $2.5 million in FY 2019 to fund 3-5 awards.
      Letter of Intent due: January 26, 2019
      Application due: February 26, 2019

    • RFA-DK-18-015: Human Pancreas Analysis Program (HPAP) 
      This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with type 1 diabetes (T1D), beta cell specific autoimmunity, or rare forms of islet dysfunction that may inform understanding of the pathogenesis of T1D , as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues and expand the existing PANC DB open-access resource database.  HPAP is a component of HIRN, created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.

      NIDDK intends to commit $4.5 million in FY 2019 to fund 1 award.
      Letter of Intent due: January 26, 2019
      Application due: February 26, 2019

    • RFA-DK-18-016: Human Pancreas Analysis Program for Type 2 Diabetes (HPAP-T2D) 
      This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, with a program goal of further advancing research through a shared resource, by tasking the team with : 1) identifying, collecting and intensively characterizing primary pancreatic tissues from patients with T2D and related forms of islet dysfunction, as well as age-matched controls; and 2) analyzing, organizing and sharing the data resulting from the study of these tissues through use and expansion of the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network (HIRN), created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in Type 1 Diabetes (T1D), and to find innovative strategies to protect and replace functional human beta cell mass.

      NIDDK intends to commit $3 million in FY 2019 to fund 1 award.
      Letter of Intent due: January 26, 2019
      Application due: February 26, 2019

    • RFA-DK-18-011: Human Islet Research Network: Consortium on Human Islet Biomimetics (CHIB)
      Invitation for new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components.  CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. 

      NIDDK intends to commit $3 million in FY 2019 to fund 2-3 awards.
      Letter of Intent due: November 11, 2018
      Application due: December 11, 2018

  • NIH Requests for Applications (RFAs):

    • NOT-RM-17-030: National Center for Advancing Translational Studies (NCATS)’s Stem Cell Translational Laboratory is seeking new collaborations to to help achieve common goals in induced pluripotent stem cell (iPSC) biology in a faster and more coordinated fashion. Interested investigators may submit proposals on July 1, November 1 and March 1 to collaborate with SCTL throughout the year.

    • RFA-PAR-18-886: New Paradigms in Tissue Communication-from mediators to metabolic function (RC2 Clinical Trials Optional)
      NIDDK utilizes High Impact, Interdisciplinary Science (RC2) grants to support projects that will lay the foundation for new fields of investigation within the mission of NIDDK.  The RC2 is envisioned to use an interdisciplinary approach to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community.

      This targeted FOA specifically seeks to generate scientific advancements that are focused on identifying new signals and regulatory networks that mediate metabolic cross talks within and between organs that play a role in the development of diabetes and obesity.  The interdisciplinary approaches proposed should be designed to foster novel synergies that will accelerate conceptual and technical breakthroughs in science related to metabolic tissue communication

      Application due dates: Nov 1, 2019; May 30, 2019, October 31, 2019; June 2, 2020

    • NIH Regenerative Medicine Innovation Projects

    • RFA-DK-18-005: Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)
      NIDDK intends to commit $3.25 million in FY 2019 to fund 4-5 awards.
      Letter of Intent due: November 6, 2018
      Application due: December 6, 2018

    • RFA-DK-17-031The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional)
      NIDDK intends to commit up to $1.25 million to fund 2-3 awards in FY 2018 and up to $1.25 million to fund 2-3 awards in FY 2019.
      Letter of Intent due: March 26, 2018 and November 6, 2018
      Application due: April 26, 2018 and December 6, 2018